Landmark Bancorp Reports 44.4% Increase in Net Earnings for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy LARK?
Source: Newsfilter
- Net Earnings Growth: Landmark Bancorp reported net earnings of $18.8 million for 2025, a 44.4% increase from $13.0 million in 2024, primarily driven by strong growth in net interest income and well-controlled non-interest expenses.
- Earnings Per Share Improvement: The diluted earnings per share for Q4 2025 was $0.77, showing a decrease from $0.81 in Q3 but a significant increase from $0.54 in the same quarter last year, reflecting ongoing improvements in profitability.
- Enhanced Capital Ratios: As of December 31, 2025, the tangible common equity to assets ratio increased to 8.03%, demonstrating robust capital management that helps bolster market confidence.
- Dividend Declaration: The Board declared a quarterly cash dividend of $0.21 per share, payable on February 26, 2026, to common stockholders of record as of February 12, 2026, highlighting the company's commitment to shareholder returns.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LARK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LARK
About LARK
Landmark Bancorp, Inc. is the holding company for Landmark National Bank (the Bank). The Bank is a community banking organization engaged in providing financial and banking services. The Company’s business consists of the ownership of the Bank and Landmark Risk Management, Inc. The Bank’s primary deposit gathering and lending markets are geographically diversified throughout central, eastern, southeast, and southwest Kansas. The Bank is principally engaged in the business of attracting deposits from the general public and using such deposits, together with borrowings and other funds, to originate one-to-four family residential real estate, construction and land, commercial real estate (CRE), commercial, agriculture, municipal and consumer loans. The Bank also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Landmark Risk Management, Inc. provides property and casualty insurance coverage to the Company and the Bank.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Landmark Bancorp Reports Strong Q4 2025 Earnings Growth
- Net Income Growth: Landmark Bancorp reported a net income of $4.7 million for Q4 2025, translating to diluted earnings per share of $0.77, which marks a significant increase from $3.3 million in Q4 2024, highlighting the company's robust profitability amid rising net interest income.
- Increase in Net Interest Income: The bank's net interest income reached $14.8 million in Q4, up $695,000 from the previous quarter, driven by improved asset yields and lower funding costs, thereby strengthening the company's financial position.
- Improvement in Nonperforming Loans: Nonperforming loans decreased slightly to just under $10 million, representing 0.90% of gross loans, down $3.1 million from year-end 2024, reflecting effective credit quality monitoring and risk management strategies.
- Continued Shareholder Returns: The board declared a cash dividend of $0.21 per share to be paid on February 26, 2026, marking the 98th consecutive quarterly cash dividend, which underscores the company's commitment to returning value to shareholders.
See More
Landmark Bancorp Reports 44.4% Increase in Net Earnings for 2025
- Net Earnings Growth: Landmark Bancorp reported net earnings of $18.8 million for 2025, a 44.4% increase from $13.0 million in 2024, primarily driven by strong growth in net interest income and well-controlled non-interest expenses.
- Earnings Per Share Improvement: The diluted earnings per share for Q4 2025 was $0.77, showing a decrease from $0.81 in Q3 but a significant increase from $0.54 in the same quarter last year, reflecting ongoing improvements in profitability.
- Enhanced Capital Ratios: As of December 31, 2025, the tangible common equity to assets ratio increased to 8.03%, demonstrating robust capital management that helps bolster market confidence.
- Dividend Declaration: The Board declared a quarterly cash dividend of $0.21 per share, payable on February 26, 2026, to common stockholders of record as of February 12, 2026, highlighting the company's commitment to shareholder returns.
See More
Landmark Bancorp (LARK) to Release Q4 2025 Earnings on January 28, 2026
- Earnings Release Schedule: Landmark Bancorp will release its Q4 2025 earnings after market close on January 28, 2026, which is expected to provide investors with crucial financial performance data to assess the company's future growth potential.
- Conference Call Timing: The company will host a conference call on January 29, 2026, at 10:00 am CT to discuss the earnings results, aiming to enhance communication with investors and improve transparency and trust.
- Replay Information: A replay of the earnings call will be available until February 5, 2026, allowing investors who missed the live event to access key information by dialing (866) 813-9403 and using access code 974716.
- Company Background: Landmark Bancorp, headquartered in Manhattan, Kansas, operates 29 branches and is dedicated to providing quality financial services, thereby strengthening its competitive position in the local market.
See More
Landmark Bancorp Named to Piper Sandler's SM-All Stars Class of 2025
- Honor Recognition: Landmark Bancorp has been named one of the 24 top-performing small-cap banks in the U.S. by Piper Sandler for its 2025 SM-All Stars Class, showcasing its excellence in growth, profitability, and capital strength.
- New Member: As one of six new banks recognized this year, Landmark stands out in a competitive financial landscape, further solidifying its market position and reputation.
- Community Banking Mission: CEO Abby Wendel emphasized that this honor reflects the dedication of the team and the support of the Board, highlighting their commitment to building personalized relationships with clients as a community bank.
- Service Network Expansion: With 29 branches across 23 communities in Kansas, Landmark National Bank continues to drive local economic development, enhancing its influence in the regional market.
See More
Daily Upgrade Report for Validea Martin Zweig Strategy - December 4, 2025
Validea's Growth Investor Model: Today's upgrades for Validea's Growth Investor model highlight LANDMARK BANCORP INC (LARK), which saw its rating increase from 74% to 89% based on strong fundamentals and valuation metrics.
Company Overview: Landmark Bancorp, Inc. operates as a community banking organization in Kansas, providing a range of financial services including residential and commercial loans, as well as property and casualty insurance through its subsidiary.
Martin Zweig's Investment Strategy: The strategy emphasizes growth stocks with accelerating earnings and sales growth, reasonable valuations, and low debt, with scores above 80% indicating interest in the stock.
Validea's Research Service: Validea offers investment research based on the strategies of renowned investors like Martin Zweig, aiming to provide stock analysis and model portfolios that have historically outperformed the market.
See More
Larkspur Biosciences Initiates Phase 1 Trial of LRK-4189 Targeting 85% of Colorectal Cancer Patients
- Clinical Trial Launch: Larkspur Biosciences has initiated a Phase 1 clinical trial of LRK-4189 in healthy volunteers to evaluate its safety and pharmacokinetics, with plans to enroll approximately 40 participants, thereby laying the groundwork for subsequent patient studies.
- Targeted Therapy Innovation: As the first-in-class targeted protein degrader of PIP4K2C, LRK-4189 addresses 85% of colorectal cancer patients, signaling a significant breakthrough in treating hard-to-treat tumors and potentially transforming existing treatment paradigms.
- Biomarker Validation: Preclinical data indicate that LRK-4189 demonstrates favorable safety and measurable biomarker activity, suggesting that its application in healthy volunteers will help define biologically meaningful doses, thereby enhancing clinical efficacy.
- Cancer Adaptation Research: PIP4K2C is broadly expressed in various cancers, and Larkspur's research will delve into how cancer cells evade immune surveillance through this pathway, driving new directions in cancer treatment.
See More
Landmark Bancorp Reports Strong Q4 2025 Earnings Growth
- Net Income Growth: Landmark Bancorp reported a net income of $4.7 million for Q4 2025, translating to diluted earnings per share of $0.77, which marks a significant increase from $3.3 million in Q4 2024, highlighting the company's robust profitability amid rising net interest income.
- Increase in Net Interest Income: The bank's net interest income reached $14.8 million in Q4, up $695,000 from the previous quarter, driven by improved asset yields and lower funding costs, thereby strengthening the company's financial position.
- Improvement in Nonperforming Loans: Nonperforming loans decreased slightly to just under $10 million, representing 0.90% of gross loans, down $3.1 million from year-end 2024, reflecting effective credit quality monitoring and risk management strategies.
- Continued Shareholder Returns: The board declared a cash dividend of $0.21 per share to be paid on February 26, 2026, marking the 98th consecutive quarterly cash dividend, which underscores the company's commitment to returning value to shareholders.
See More
Landmark Bancorp Reports 44.4% Increase in Net Earnings for 2025
- Net Earnings Growth: Landmark Bancorp reported net earnings of $18.8 million for 2025, a 44.4% increase from $13.0 million in 2024, primarily driven by strong growth in net interest income and well-controlled non-interest expenses.
- Earnings Per Share Improvement: The diluted earnings per share for Q4 2025 was $0.77, showing a decrease from $0.81 in Q3 but a significant increase from $0.54 in the same quarter last year, reflecting ongoing improvements in profitability.
- Enhanced Capital Ratios: As of December 31, 2025, the tangible common equity to assets ratio increased to 8.03%, demonstrating robust capital management that helps bolster market confidence.
- Dividend Declaration: The Board declared a quarterly cash dividend of $0.21 per share, payable on February 26, 2026, to common stockholders of record as of February 12, 2026, highlighting the company's commitment to shareholder returns.
See More
Landmark Bancorp (LARK) to Release Q4 2025 Earnings on January 28, 2026
- Earnings Release Schedule: Landmark Bancorp will release its Q4 2025 earnings after market close on January 28, 2026, which is expected to provide investors with crucial financial performance data to assess the company's future growth potential.
- Conference Call Timing: The company will host a conference call on January 29, 2026, at 10:00 am CT to discuss the earnings results, aiming to enhance communication with investors and improve transparency and trust.
- Replay Information: A replay of the earnings call will be available until February 5, 2026, allowing investors who missed the live event to access key information by dialing (866) 813-9403 and using access code 974716.
- Company Background: Landmark Bancorp, headquartered in Manhattan, Kansas, operates 29 branches and is dedicated to providing quality financial services, thereby strengthening its competitive position in the local market.
See More
Landmark Bancorp Named to Piper Sandler's SM-All Stars Class of 2025
- Honor Recognition: Landmark Bancorp has been named one of the 24 top-performing small-cap banks in the U.S. by Piper Sandler for its 2025 SM-All Stars Class, showcasing its excellence in growth, profitability, and capital strength.
- New Member: As one of six new banks recognized this year, Landmark stands out in a competitive financial landscape, further solidifying its market position and reputation.
- Community Banking Mission: CEO Abby Wendel emphasized that this honor reflects the dedication of the team and the support of the Board, highlighting their commitment to building personalized relationships with clients as a community bank.
- Service Network Expansion: With 29 branches across 23 communities in Kansas, Landmark National Bank continues to drive local economic development, enhancing its influence in the regional market.
See More
Daily Upgrade Report for Validea Martin Zweig Strategy - December 4, 2025
Validea's Growth Investor Model: Today's upgrades for Validea's Growth Investor model highlight LANDMARK BANCORP INC (LARK), which saw its rating increase from 74% to 89% based on strong fundamentals and valuation metrics.
Company Overview: Landmark Bancorp, Inc. operates as a community banking organization in Kansas, providing a range of financial services including residential and commercial loans, as well as property and casualty insurance through its subsidiary.
Martin Zweig's Investment Strategy: The strategy emphasizes growth stocks with accelerating earnings and sales growth, reasonable valuations, and low debt, with scores above 80% indicating interest in the stock.
Validea's Research Service: Validea offers investment research based on the strategies of renowned investors like Martin Zweig, aiming to provide stock analysis and model portfolios that have historically outperformed the market.
See More
Larkspur Biosciences Initiates Phase 1 Trial of LRK-4189 Targeting 85% of Colorectal Cancer Patients
- Clinical Trial Launch: Larkspur Biosciences has initiated a Phase 1 clinical trial of LRK-4189 in healthy volunteers to evaluate its safety and pharmacokinetics, with plans to enroll approximately 40 participants, thereby laying the groundwork for subsequent patient studies.
- Targeted Therapy Innovation: As the first-in-class targeted protein degrader of PIP4K2C, LRK-4189 addresses 85% of colorectal cancer patients, signaling a significant breakthrough in treating hard-to-treat tumors and potentially transforming existing treatment paradigms.
- Biomarker Validation: Preclinical data indicate that LRK-4189 demonstrates favorable safety and measurable biomarker activity, suggesting that its application in healthy volunteers will help define biologically meaningful doses, thereby enhancing clinical efficacy.
- Cancer Adaptation Research: PIP4K2C is broadly expressed in various cancers, and Larkspur's research will delve into how cancer cells evade immune surveillance through this pathway, driving new directions in cancer treatment.
See More
